RS55201B1 - Antimalarijski agensi - Google Patents

Antimalarijski agensi

Info

Publication number
RS55201B1
RS55201B1 RS20160814A RSP20160814A RS55201B1 RS 55201 B1 RS55201 B1 RS 55201B1 RS 20160814 A RS20160814 A RS 20160814A RS P20160814 A RSP20160814 A RS P20160814A RS 55201 B1 RS55201 B1 RS 55201B1
Authority
RS
Serbia
Prior art keywords
phenyl
group
pyrazin
amino
trifluoromethyl
Prior art date
Application number
RS20160814A
Other languages
English (en)
Serbian (sr)
Inventor
Yassir Younis
Kelly Chibale
Michael John Witty
David Waterson
Original Assignee
Univ Cape Town
Medicines For Malaria Venture Mmv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cape Town, Medicines For Malaria Venture Mmv filed Critical Univ Cape Town
Publication of RS55201B1 publication Critical patent/RS55201B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RS20160814A 2012-02-17 2013-02-15 Antimalarijski agensi RS55201B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
EP13712926.8A EP2814820B1 (en) 2012-02-17 2013-02-15 Anti-malarial agents
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents

Publications (1)

Publication Number Publication Date
RS55201B1 true RS55201B1 (sr) 2017-01-31

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160814A RS55201B1 (sr) 2012-02-17 2013-02-15 Antimalarijski agensi

Country Status (21)

Country Link
US (1) US9266842B2 (2)
EP (1) EP2814820B1 (2)
JP (1) JP6226889B2 (2)
CN (1) CN104136426B (2)
BR (1) BR112014020212B1 (2)
CA (1) CA2864483A1 (2)
CY (1) CY1118074T1 (2)
DK (1) DK2814820T3 (2)
ES (1) ES2589283T3 (2)
HR (1) HRP20161237T1 (2)
HU (1) HUE029876T2 (2)
IN (1) IN2014MN01622A (2)
LT (1) LT2814820T (2)
ME (1) ME02535B (2)
PL (1) PL2814820T3 (2)
PT (1) PT2814820T (2)
RS (1) RS55201B1 (2)
SI (1) SI2814820T1 (2)
SM (1) SMT201600441B (2)
WO (1) WO2013121387A1 (2)
ZA (1) ZA201406786B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2814820T (lt) * 2012-02-17 2016-10-25 University Of Cape Town Antimaliariniai agentai
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
ES2928240T3 (es) * 2018-01-24 2022-11-16 Glaxosmithkline Ip Dev Ltd Compuestos novedosos para el tratamiento de infecciones parasitarias
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
US20250122167A1 (en) * 2021-11-23 2025-04-17 Glaxosmithkline Intellectual Property Development Limited Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection
JP2025531008A (ja) 2022-08-09 2025-09-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング フロピリミジン誘導体
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545422C (en) * 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
US20080039450A1 (en) * 2006-06-22 2008-02-14 Jensen Annika J Compounds
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5735986B2 (ja) * 2010-01-18 2015-06-17 エムエムヴィ メディシンズ フォア マラリア ヴェンチャーMmv Medicines For Malaria Venture 新規抗マラリア剤
US9062008B2 (en) * 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2828578A1 (en) * 2011-03-04 2012-09-13 Lexicon Pharmaceuticals, Inc. Mst1 kinase inhibitors and methods of their use
LT2814820T (lt) * 2012-02-17 2016-10-25 University Of Cape Town Antimaliariniai agentai

Also Published As

Publication number Publication date
BR112014020212A8 (pt) 2018-01-23
JP2015507004A (ja) 2015-03-05
EP2814820A1 (en) 2014-12-24
PT2814820T (pt) 2016-10-25
US9266842B2 (en) 2016-02-23
IN2014MN01622A (2) 2015-05-15
CY1118074T1 (el) 2017-06-28
DK2814820T3 (en) 2016-10-03
WO2013121387A1 (en) 2013-08-22
CN104136426B (zh) 2017-10-03
SMT201600441B (it) 2017-01-10
SI2814820T1 (sl) 2016-10-28
CN104136426A (zh) 2014-11-05
ES2589283T3 (es) 2016-11-11
ZA201406786B (en) 2015-06-24
JP6226889B2 (ja) 2017-11-08
US20150031682A1 (en) 2015-01-29
CA2864483A1 (en) 2013-08-22
LT2814820T (lt) 2016-10-25
HRP20161237T1 (hr) 2016-11-04
BR112014020212B1 (pt) 2021-11-23
ME02535B (me) 2017-02-20
PL2814820T3 (pl) 2017-01-31
HUE029876T2 (en) 2017-04-28
EP2814820B1 (en) 2016-07-20
HK1202859A1 (en) 2015-10-09

Similar Documents

Publication Publication Date Title
CN112424174B (zh) 可用于治疗疾病的杂环化合物
JP2024079762A (ja) Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
TWI753946B (zh) 具有glp-1受體促效作用的吡唑并吡啶衍生物
JP5735986B2 (ja) 新規抗マラリア剤
RS55201B1 (sr) Antimalarijski agensi
CA2872110C (en) Nitrogenous heterocyclic derivatives and their application in drugs
US12234218B2 (en) Heterocyclic compounds as modulators of mGluR7
AU2015266453C1 (en) Alk kinase inhibitor, and preparation method and use thereof
CN107148417A (zh) 苯并氮杂*磺酰胺化合物
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
JP2023543254A (ja) ピリド[4,3-b]インドール誘導体およびその医薬としての使用
JP2019065020A (ja) キヌレニン−3−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
RS55998B1 (sr) Novi anti-malarijski agensi
CN118339149A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
HK1202859B (en) Anti -malarial agents
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
WO2024233280A1 (en) Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7
WO2026002036A1 (zh) 一种化合物及其用途